Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SM-88 (MPS) in Ewing's Sarcoma and Advanced Sarcoma
NCT03778996Phase 2Active, not recruiting
- Sponsor
- Cancer Institute Medical Group
- Start
- Jan 2020
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of racemetyrosine in Ewing sarcoma and sarcoma (2 arms), sponsored by Cancer Institute Medical Group. Primary endpoints: Overall Response Rate, Stable Disease for at Least 3 Months and 1 more. Started Jan 2020; status: active, not recruiting.
02
Drugs
racemetyrosine
03
Conditions
Ewing sarcomasarcoma
Beyond the preview
Go deeper on NCT03778996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03778996.